Prostate cancer is the most common cancer in men in the UK, but more than 8 in 10 (84%) of patients now survive their disease for 10 years or more. We are at the heart of this progress – playing pivotal roles in the development of treatments like abiraterone and intensity modulated radiotherapy.
From studying the biology of prostate cancer cells in the lab to leading clinical trials testing cutting-edge treatments, our researchers are working hard to ensure more men survive prostate cancer.
Thanks to research, we've helped change the outlook for men with prostate cancer.
Meet people like Alfred who have experienced first-hand how our research is making a difference. The life-saving research we do wouldn’t be possible without your support.
Over the last 40 years, cancer survival in the UK has doubled. In the 1970s just 1 in 4 people survived their disease for 10 years or more. Today 2 in 4 survive.
We want to accelerate progress and see 3 in 4 patients surviving the disease by 2034.
Browse the latest news, analysis and opinion from Cancer Research UK.
Want to find more information about our research or prostate cancer?
